Will the Covid-19 vaccine change the long-term trends?

Equities 4 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  In today's equity update we take a look at the market reaction to the news from Pfizer announcing great results on its Covid-19 vaccine. Good news has been bad news for the markets with many trades reversing causing a big jolt to momentum and technology stocks. However, is this short-term reaction the start of something longer term with value outperforming growth/momentum, or European equities suddenly outperforming US equities? In our view the long trend since 2009 is not broken and technology stocks will continue to deliver the best risk-reward ratio for long-term investors. The key risk is obviously where interest rates go as growth stocks are more sensitive to interest rates.


The news yesterday from Pfizer announcing that its Covid-19 vaccine is 90% effective significantly exceeding the market expectations of 60-70% gave a big jolt to equity markets. S&P 500 jumped more than 3% on the news driven by the energy, financials, and industrials sectors. Sitting opposite this reaction function was technology stocks with the Nasdaq 100 futures correcting significantly lower with the weakness extending in today’s session. As the chart below shows, European equities are benefitting the most from the vaccine as the European economy is hit hard from Covid-19 and generally European equities are more cyclical than the overall US equity markets.

Source: Bloomberg

The market reaction over the past 48 hours beg the question whether many of the assumptions among investors are wrong and whether many “obvious” trades will reverse over a longer period. If one zooms out the Covid-19 and the vaccine news could suddenly give the impression that technology stocks are not worth owning any longer. But looking at it from a longer time perspective US technology stocks have had explosive earnings growth since 2009 while also being more immune to crises such as the euro area crisis in 2011-2012, emerging markets and USD in 2015, and lately Covid-19. This long-term trend will not change because of a vaccine and thus investors will likely revert to the same conclusion which is that this is the fastest growing segment of the market and where the future lies. We remain positive and overweight the technology segment and still sceptical of European equities still dominated by financials. The key risk to our positive view on technology stocks over the next year is rising interest rates which will have larger negative impact on growth stocks than value stocks.

In the short-term a lot views will LAO be updated for the travel and leisure segment across the world. The table below shows the general positive price action today in Europe across this hard-hit segment. Due to the vaccine uncertainty in terms of safety and delivery this segment will likely experience a lot of volatility in the coming months providing excellent trading opportunities.

Source: Bloomberg

The chart below is for regulatory purposes

Source: Bloomberg
Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide and Product Disclosure Statement to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.
Please click here to view our full disclaimer.